TY - JOUR
T1 - Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer
AU - Malihi, Paymaneh D.
AU - Graf, Ryon P.
AU - Rodriguez, Angel
AU - Ramesh, Naveen
AU - Lee, Jerry
AU - Sutton, Ramsay
AU - Jiles, Rhett
AU - Velasco, Carmen Ruiz
AU - Sei, Emi
AU - Kolatkar, Anand
AU - Logothetis, Christopher
AU - Navin, Nicholas E.
AU - Corn, Paul
AU - Aparicio, Ana M.
AU - Dittamore, Ryan
AU - Hicks, James
AU - Kuhn, Peter
AU - Zurita, Amado J.
N1 - Funding Information:
We would like to thank the patients participating on trial NCT01505868 and their families for contributing to this clinical research. We would additionally like to thank the laboratory staffs at the Eckstein Tissue Acquisition Laboratory at MD Anderson and at Epic Sciences. This work is funded in whole or in part by the Prostate Cancer Foundation Award 17CHAL01 (A.M. Aparicio, P. Kuhn, J. Hicks), the Solon Scott III Prostate Cancer Research Fund (P. Corn), David and Janet Polak Foundation Fellowship in Convergent Science (P.D. Malihi), and the CPRIT Research Training Program RP170067 (N. Ramesh).
Funding Information:
R.P Graf is an employee of Epic Sciences. A. Rodriguez holds ownership interest (including patents) in Epic Sciences. R. Sutton is an employee of Epic Sciences. R. Jiles holds ownership interest (including patents) in Epic Sciences. A. Kolatkar holds ownership interest (including patents) in Epic Sciences. R. Dittamore is an employee of Epic Sciences. J. Hicks holds ownership interest (including patents) in and is an unpaid consultant/advisory board member for Epic Sciences. P. Kuhn holds ownership interest (including patents) in and is an unpaid consultant/advisory board member for Epic Sciences. A.J. Zurita reports receiving commercial research grants from Infinity Pharmaceuticals; reports receiving speakers bureau honoraria from Pfizer Oncology; and reports receiving other remuneration from Bayer. No potential conflicts of interest were disclosed by the other authors.
Publisher Copyright:
©2020 American Association for Cancer Research.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Purpose: Aggressive variant prostate cancer (AVPC) represents a clinical subset distinguished by therapy resistance and poor prognosis, linked to combined losses of the tumor suppressor genes (TSG) PTEN, RB1, and TP53. Circulating tumor cells (CTC) provide a minimally invasive opportunity for identification and molecular characterization of AVPC. We aimed to evaluate the incidence and clinical significance of compound (2þ)TSG losses and genomic instability in prostate cancer CTC, and to expand the set genomic biomarkers relevant to AVPC. Experimental Design: Genomic analysis of chromosomal copy-number alterations (CNA) at single-cell resolution was performed in CTC from patients with and without AVPC before initiating chemotherapy with cabazitaxel or cabazitaxel and carboplatin. We evaluated associations between single-CTC genomics and clinical features, progression-free survival, and overall survival. Results: A total of 257 individual CTC were sequenced from 47 patients (1–22 CTC/patient). Twenty patients (42.6%) had concurrent 2þTSG losses in at least one CTC in association with poor survival and increased genomic instability, inferred by high large-scale transitions scores. Higher LST in CTC were independent of CTC enumerated, clinically more indicative of aggressive behavior than co-occurring TSG losses, and molecularly associated with gains in chromosomal regions including PTK2, Myc, and NCOA2; increased androgen receptor expression; and BRCA2 loss. In 57 patients with matched cell-free tumor DNA data, CTC were more frequently detectable and evaluable for CNA analysis (in 73.7% vs. 42.1%, respectively). Conclusions: Our findings suggest that genomic instability in CTC is a hallmark of advanced prostate cancer aggressiveness, and support single-CTC sequencing as a compelling tool to noninvasively characterize cancer heterogeneity.
AB - Purpose: Aggressive variant prostate cancer (AVPC) represents a clinical subset distinguished by therapy resistance and poor prognosis, linked to combined losses of the tumor suppressor genes (TSG) PTEN, RB1, and TP53. Circulating tumor cells (CTC) provide a minimally invasive opportunity for identification and molecular characterization of AVPC. We aimed to evaluate the incidence and clinical significance of compound (2þ)TSG losses and genomic instability in prostate cancer CTC, and to expand the set genomic biomarkers relevant to AVPC. Experimental Design: Genomic analysis of chromosomal copy-number alterations (CNA) at single-cell resolution was performed in CTC from patients with and without AVPC before initiating chemotherapy with cabazitaxel or cabazitaxel and carboplatin. We evaluated associations between single-CTC genomics and clinical features, progression-free survival, and overall survival. Results: A total of 257 individual CTC were sequenced from 47 patients (1–22 CTC/patient). Twenty patients (42.6%) had concurrent 2þTSG losses in at least one CTC in association with poor survival and increased genomic instability, inferred by high large-scale transitions scores. Higher LST in CTC were independent of CTC enumerated, clinically more indicative of aggressive behavior than co-occurring TSG losses, and molecularly associated with gains in chromosomal regions including PTK2, Myc, and NCOA2; increased androgen receptor expression; and BRCA2 loss. In 57 patients with matched cell-free tumor DNA data, CTC were more frequently detectable and evaluable for CNA analysis (in 73.7% vs. 42.1%, respectively). Conclusions: Our findings suggest that genomic instability in CTC is a hallmark of advanced prostate cancer aggressiveness, and support single-CTC sequencing as a compelling tool to noninvasively characterize cancer heterogeneity.
UR - http://www.scopus.com/inward/record.url?scp=85089126804&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089126804&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-4100
DO - 10.1158/1078-0432.CCR-19-4100
M3 - Article
C2 - 32341031
AN - SCOPUS:85089126804
SN - 1078-0432
VL - 26
SP - 4143
EP - 4153
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 15
ER -